Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > Deadline for FDA review of Anktiva (N-803) April 23

<< Previous

Bullboard Posts

Next >>

Comment by Eoganachton Mar 06, 2024 1:15pm

312 Views

Post# 35918463

RE:RE:Deadline for FDA review of Anktiva (N-803) April 23

If all the remaining patients are treated by the end of 2024 Theralase will be able to submit an application by mid-2026.

If that happens and Theralase gets priority review there could be an FDA decision by the end of 2026.